Literature DB >> 16908860

NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.

C A Colton1, M P Vitek, D A Wink, Q Xu, V Cantillana, M L Previti, W E Van Nostrand, J B Weinberg, B Weinberg, H Dawson.   

Abstract

Alzheimer's disease is characterized by two primary pathological features: amyloid plaques and neurofibrillary tangles. The interconnection between amyloid and tau aggregates is of intense interest, but mouse models have yet to reveal a direct interrelationship. We now show that NO may be a key factor that connects amyloid and tau pathologies. Genetic removal of NO synthase 2 in mice expressing mutated amyloid precursor protein results in pathological hyperphosphorylation of mouse tau, its redistribution to the somatodendritic compartment in cortical and hippocampal neurons, and aggregate formation. Lack of NO synthase 2 in the amyloid precursor protein Swedish mutant mouse increased insoluble beta-amyloid peptide levels, neuronal degeneration, caspase-3 activation, and tau cleavage, suggesting that NO acts at a junction point between beta-amyloid peptides, caspase activation, and tau aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908860      PMCID: PMC1550768          DOI: 10.1073/pnas.0601075103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

2.  In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals.

Authors:  L M Sayre; G Perry; P L Harris; Y Liu; K A Schubert; M A Smith
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

3.  Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.

Authors:  Y Tomidokoro; K Ishiguro; Y Harigaya; E Matsubara; M Ikeda; J M Park; K Yasutake; T Kawarabayashi; K Okamoto; M Shoji
Journal:  Neurosci Lett       Date:  2001-02-23       Impact factor: 3.046

4.  Fibrillary beta-amyloid deposits are closely associated with atrophic nitric oxide synthase (NOS)-expressing neurons but do not upregulate the inducible NOS in transgenic Tg2576 mouse brain with Alzheimer pathology.

Authors:  M Hartlage-Rübsamen; J Apelt; R Schliebs
Journal:  Neurosci Lett       Date:  2001-04-20       Impact factor: 3.046

5.  Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes.

Authors:  K Duff; H Knight; L M Refolo; S Sanders; X Yu; M Picciano; B Malester; M Hutton; J Adamson; M Goedert; K Burki; P Davies
Journal:  Neurobiol Dis       Date:  2000-04       Impact factor: 5.996

6.  Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques.

Authors:  S C Lee; M L Zhao; A Hirano; D W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  1999-11       Impact factor: 3.685

7.  Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice.

Authors:  S Capsoni; G Ugolini; A Comparini; F Ruberti; N Berardi; A Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  Conformational change as one of the earliest alterations of tau in Alzheimer's disease.

Authors:  C L Weaver; M Espinoza; Y Kress; P Davies
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

9.  Microglial contribution to oxidative stress in Alzheimer's disease.

Authors:  C A Colton; O N Chernyshev; D L Gilbert; M P Vitek
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 10.  Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration.

Authors:  S M de la Monte; B X Lu; Y K Sohn; D Etienne; J Kraft; N Ganju; J R Wands
Journal:  Neurobiol Aging       Date:  2000 Mar-Apr       Impact factor: 4.673

View more
  60 in total

Review 1.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

2.  Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.

Authors:  Petr Novak; Martin Cente; Nina Kosikova; Tomas Augustin; Richard Kvetnansky; Michal Novak; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2017-04-12       Impact factor: 5.046

3.  Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase.

Authors:  Michael D Hoos; Brenna M Richardson; Matthew W Foster; Angela Everhart; J Will Thompson; M Arthur Moseley; Carol A Colton
Journal:  J Proteome Res       Date:  2013-09-18       Impact factor: 4.466

Review 4.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

5.  Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.

Authors:  D Hutchinson; V Ho; M Dodd; H N Dawson; A C Zumwalt; D Schmitt; C A Colton
Journal:  Neuroscience       Date:  2007-07-21       Impact factor: 3.590

Review 6.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

7.  The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease.

Authors:  Alexandra Badea; Lauren Kane; Robert J Anderson; Yi Qi; Mark Foster; Gary P Cofer; Neil Medvitz; Anne F Buckley; Andreas K Badea; William C Wetsel; Carol A Colton
Journal:  Neuroimage       Date:  2016-08-10       Impact factor: 6.556

Review 8.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

9.  In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP(SW) and APP(SW)/PS1(L166P) Alzheimer's transgenic mice.

Authors:  Malgorzata Duszczyk; Magdalena Kuszczyk; Maitea Guridi; Jerzy W Lazarewicz; Martin J Sadowski
Journal:  Neurochem Int       Date:  2012-07-27       Impact factor: 3.921

Review 10.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.